What question did this study set out to answer?

This study aims to analyze whether senescent peritoneal cells release exosomes that contribute to reactivation of dormant ovarian cancer cells.

April 25, 2026Cancers0 citationsOpen Access

View Full Paper

Exosomes Generated by Normal Peritoneal Cells Driven to Senescence by Carboplatin and Paclitaxel Awaken Dormant Ovarian Cancer Cells and Support Their Growth Reinitiation In Vitro

SRSzymon RuteckiPoznan University of Medical Sciences AKAdrianna KrawiecPoznan University of Medical Sciences ALA. Leśniewska-BocianowskaPoznan University of Medical Sciences

Key Points

This study aims to analyze whether senescent peritoneal cells release exosomes that contribute to reactivation of dormant ovarian cancer cells.
Investigated exosome secretion from senescent peritoneal mesothelial cells and fibroblasts after carboplatin and paclitaxel exposure.
Assessed the reactivation effect on dormant ovarian cancer cell lines (A2780, OVCAR-3, SKOV-3) using exosomes compared to non-exosomal media.
Conducted compositional analysis of exosomes from young and senescent cells to determine differences in contents.
Senescent PMCs secreted exosomes that significantly reactivated dormant EOC cells, enhancing migration and invasion (p<0.01).
Senescent PMC-derived exosomes displayed reduced miR-210-3p, miR-409-3p, and miR-421, but increased MMP1 and VEGF levels.
Senescent PFB exosomes upregulated factors like CCL11 and TGF-β1 influencing cancer cell behavior.

Abstract

Background: Recurrence poses a major challenge in epithelial ovarian cancer (EOC), often occurring despite optimal first-line therapy. Dormant cancer cells are believed to play a key role, yet the mechanisms driving their reactivation remain unclear. This study examined whether exosomes released by normal peritoneal mesothelial cells (PMCs) and fibroblasts (PFBs) undergoing iatrogenic senescence after carboplatin and paclitaxel exposure contribute to EOC recurrence. Methods and Results: Senescent PMCs and PFBs secreted markedly more exosomes, identified by CD9, CD63, and CD81, compared with young cells. Exosomes from both cell types more effectively reactivated dormant EOC cells (pEOCs, A2780, OVCAR-3, SKOV-3) than non-exosomal medium constituents. Importantly, senescent PMC-derived exosomes most strongly reactivated pEOCs and SKOV-3, whereas those from senescent PFBs exerted greater effects on pEOCs, OVCAR-3, and SKOV-3. Kinetic studies of exosome internalization revealed that this process was generally more efficient in the presence of exosomes derived from senescent cells compared with those from young donor cells. Compositional analysis revealed distinct profiles between young and senescent exosomes compared in two variants: young PMCs/senescent PMCs and young PFBs/senescent PFBS. Senescent PMC exosomes displayed reduced miR-210-3p, miR-409-3p, and miR-421, alongside elevated MMP1, MMP3, and VEGF, while senescent PFB exosomes showed increased amphiregulin and osteopontin but lower MMP1, MMP3, TIMP1, bFGF, VEGF, and HGF. Functionally, senescent PMC exosomes enhanced pEOC migration, invasion, and spheroid formation, and induced the expression of CCL11 and ABCB1. Senescent PFB exosomes promoted migration and upregulated CCL11, TGF-β1, BIRC5, and CHEK1. Conclusions: These findings suggest that therapy-induced senescence in peritoneal cells may contribute to EOC recurrence by reactivating dormant tumor cells through exosomal signaling.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Exosomes Generated by Normal Peritoneal Cells Driven to Senescence by Carboplatin and Paclitaxel Awaken Dormant Ovarian Cancer Cells and Support Their Growth Reinitiation In Vitro

Key Points

Abstract

Cite This Study

Also Consider

Also Consider